News Sentiment

DBVT sentiment intelligence

DBV Technologies news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 16.49 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+4.2% over one week, -5.3% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

DBV Technologies Q2 Earnings Call Highlights

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction 4.2% Price confirming higher
Trend fit Trend inactive -5.3% over four weeks
Fair value 58.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 36
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 8
Stock Titan 6
Idéal Investisseur 5
GlobeNewswire 4
MarketBeat 3
scanx.trade 2
markets.businessinsider.com 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 20
Analyst action 3
Deals and strategy 3
Guidance 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Quartr Direct company coverage

DBV Technologies (DBV) Q2 2026 earnings summary

DBV Technologies is transitioning to a commercial stage, with plans for BLA submission for the VIASKIN Peanut Patch in Q3 2026. The company reported a net loss of $98.0 million for H1 2026, though the net loss per share improved due to equity financing. Funding is secured into Q3

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 23:10
Source
Quartr
markets.businessinsider.com Direct company coverage

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

DBV Technologies announced its second quarter and half-year 2026 financial results, highlighting continued progress towards the Biologics License Application (BLA) submission for its Viaskin Peanut Patch in children aged 4-7, now anticipated in Q3 2026. The company reported $174.

Tone
Positive 66/100
Event
Earnings
Published
16 Jul 2026 21:10
Source
markets.businessinsider.com
markets.businessinsider.com Direct company coverage

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBV Technologies announced the filing of its Half-Year Report for the semester ending June 30, 2026, with the French market authority, AMF. The report is available on the Company's website (Investors/Financial Information section) and the AMF website (in French only). DBV Technol

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 21:10
Source
markets.businessinsider.com
TradingView Direct company coverage

DBV Technologies reports $98.0M half‑year net loss, $174.9M cash at June 30, 2026

DBV Technologies reported a net loss of $98.0 million for the first half of 2026, including a $50.4 million loss in Q2, with cash and cash equivalents of $174.9 million as of June 30, 2026, expected to fund operations into Q3 2027. The company is actively engaged with the FDA for

Tone
Negative 40/100
Event
Balance sheet
Published
16 Jul 2026 21:10
Source
TradingView
TradingView Direct company coverage

DBV Technologies S.A. 2026: Revenue $700K, EPS ($0.12) — 10-Q Summary

DBV Technologies S.A. reported its Q1 2026 results, showing revenue of $700K, a net loss of ($50.4M), and diluted loss per share of ($0.12). The company highlighted significant regulatory progress for VIASKIN® Peanut, ongoing clinical studies, and commercial readiness efforts, wi

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 20:10
Source
TradingView
Idéal Investisseur Direct company coverage

DBV Technologies Stock Breaks Its €2.75 Support Ahead of Semi-Annual Results

DBV Technologies stock is experiencing a downward trend, breaking its €2.75 support and trading below its three moving averages ahead of its semi-annual results announcement. The biotech company's stock is down 3.03% during the session, and has fallen nearly 29% over three months

Tone
Negative 30/100
Event
Earnings
Published
15 Jul 2026 10:40
Source
Idéal Investisseur
scanx.trade Direct company coverage

DBV Technologies to report Q2 2026 results on July 16

DBV Technologies is scheduled to release its second quarter 2026 financial results and provide a business update on July 16, 2026. The biopharmaceutical company will host a conference call and live webcast to discuss its performance. The company specializes in developing treatmen

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 22:20
Source
scanx.trade
Stock Titan Direct company coverage

DBV Technologies Sets Q2 2026 Results Call July 16 | DBVT Stock News

DBV Technologies announced it will report its second quarter 2026 financial results and provide a business update on July 16, 2026. The company will host an investor conference call and live audio webcast at 5:00 p.m. ET to review these results. Key details for investors include

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 20:20
Source
Stock Titan
www.timothysykes.com Direct company coverage

DBV Technologies S.A. (DBVT) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for DBV Technologies S.A. (DBVT) stock, showing a current price of $15.53 with a decrease of 2.45%. It also notes that earnings information is not currently available and lacks analyst ratings in the last three months. The content include

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 19:40
Source
www.timothysykes.com
TradingView Direct company coverage

ETFs Investing in DBV Technologies SA Sponsored ADR Stocks

This article lists Exchange Traded Funds (ETFs) that hold DBV Technologies SA Sponsored ADR stocks, sorted by market value. It provides key details for each fund, such as market value, weight, issuer, management style, expense ratio, and AUM, to help investors assess opportunitie

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 06:10
Source
TradingView
GlobeNewswire Direct company coverage

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies issued its half-year report for its liquidity contract with ODDO BHF, detailing transactions and assets from January 1, 2026, to June 30, 2026. The report showed an increase in DBV Technologies shares in the liquidity account and provided a breakdown of numerous

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 13:41
Source
GlobeNewswire
Via Ritzau Direct company coverage

DBV Technologies S.A.

DBV Technologies S.A. has issued its Half-Year Report on the liquidity contract with ODDO BHF for the period of January 1, 2026, to June 30, 2026. The report details the assets held in the liquidity account and the transactions executed within this timeframe, showing significant

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Jul 2026 20:14
Source
Via Ritzau
Stock Titan Direct company coverage

DBV Technologies posts half-year liquidity contract figures

DBV Technologies released its half-year report on the liquidity contract with ODDO BHF as of June 30, 2026. The report shows the liquidity account held 146,321 shares and €396,088.22, with significant trading volumes in the first half of 2026. This contract, governed by AMF Decis

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Jul 2026 20:10
Source
Stock Titan
Moomoo Direct company coverage

DBV Technologies Plans Q3 Filing of US Regulatory Application for Viaskin Peanut Patch

DBV Technologies announced its intention to file a regulatory application with US health authorities for its Viaskin Peanut patch in the third quarter of 2026. This move follows a pre-submission meeting with the FDA, where the company confirmed the required data for resubmission.

Tone
Positive 71/100
Event
Earnings
Published
30 Jun 2026 23:09
Source
Moomoo
TradingView Direct company coverage

Enterprise value to revenue forward of DBV Technologies SA – FWB:DBV

This page provides financial information for DBV Technologies SA (FWB:DBV) from the Frankfurt Stock Exchange, specifically focusing on its enterprise value to revenue forward. The content indicates that the market is closed and there have been no recent trades. It is presented on

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 19:39
Source
TradingView
The Manila Times Direct company coverage

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

DBV Technologies announced an update on its Biologics License Application (BLA) submission for the VIASKIN® Peanut Patch for children aged four through seven years, following extensive discussions with the FDA. The company received valuable feedback regarding the organization and

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 20:10
Source
The Manila Times
TradingView Direct company coverage

DBV Technologies to file VIASKIN Peanut Patch BLA in Q3 2026 after FDA feedback

DBV Technologies plans to submit its Biologics License Application (BLA) for the VIASKIN Peanut Patch in Q3 2026, after incorporating feedback from the FDA. The company engaged in detailed discussions with the FDA, receiving guidance on CMC and biostatistics, with no requests for

Tone
Positive 66/100
Event
Guidance
Published
29 Jun 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing

DBV Technologies announced an updated timeline for its Biologics License Application (BLA) for the VIASKIN Peanut Patch, now targeting Q3 2026 for submission. The company has engaged in detailed discussions with the FDA, which provided feedback on data organization and formatting

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:10
Source
Stock Titan